Compare HBCP & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HBCP | ESPR |
|---|---|---|
| Founded | 1908 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 453.4M | 731.9M |
| IPO Year | 2008 | 2013 |
| Metric | HBCP | ESPR |
|---|---|---|
| Price | $62.70 | $2.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $63.50 | $7.60 |
| AVG Volume (30 Days) | 123.2K | ★ 5.5M |
| Earning Date | 04-20-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.98% | N/A |
| EPS Growth | 29.01 | ★ 60.71 |
| EPS | ★ 5.87 | N/A |
| Revenue | N/A | ★ $403,135,000.00 |
| Revenue This Year | N/A | $2.92 |
| Revenue Next Year | $4.74 | N/A |
| P/E Ratio | $10.68 | ★ N/A |
| Revenue Growth | N/A | ★ 21.31 |
| 52 Week Low | $40.74 | $0.73 |
| 52 Week High | $64.17 | $4.18 |
| Indicator | HBCP | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 61.22 | 33.99 |
| Support Level | $56.27 | $1.02 |
| Resistance Level | $64.12 | $3.02 |
| Average True Range (ATR) | 1.91 | 0.20 |
| MACD | 0.28 | 0.00 |
| Stochastic Oscillator | 91.16 | 17.40 |
Home Bancorp Inc is engaged in attracting deposits from the public and using those funds to invest in loans and securities.It is holding company for Home Bank, N.A. The principal sources of funds are customer deposits, repayments of loans, repayments of investments, and funds borrowed from outside sources such as the Federal Home Loan Bank of Dallas. These funds are used for the origination of loans, including one-to-four-family first mortgage loans, home equity loans, and lines, commercial real estate loans, construction and land loans, multi-family residential loans, commercial and industrial loans, and consumer loans.
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.